At Teikoku, we offer specialized expertise in dosage form development — transforming ideas into new product opportunities. With comprehensive R&D and manufacturing capabilities, we have the expertise to not only develop drugs, but also complete the necessary steps to achieve FDA approval.

We have a dedicated R&D team - including formulation experts, analytical chemists, and regulatory specialists who are leaders in both the science and technology of delivering medications through the skin. We have a rich history of R&D achievements and a vast intellectual property portfolio, including the first medicated hydrogel and the blockbuster drug, Lidoderm — a drug that has generated more than $1 billion in revenue in less than 10 years on the market. Together, our team has pioneered the creation of three drug delivery systems: passive delivery via the Hydrohesive™ and Matrix patch technologies and active delivery via our proprietary WEDD™ (Wearable Electronic Disposable Drug delivery) technology. We are one of the two pharmaceuticals companies in the world that offers passive and active delivery.

We continue to stay on the leading edge of delivery advances, working on new methods and systems that enhance how the drugs of tomorrow are delivered.